JP2018509438A5 - - Google Patents

Download PDF

Info

Publication number
JP2018509438A5
JP2018509438A5 JP2017549483A JP2017549483A JP2018509438A5 JP 2018509438 A5 JP2018509438 A5 JP 2018509438A5 JP 2017549483 A JP2017549483 A JP 2017549483A JP 2017549483 A JP2017549483 A JP 2017549483A JP 2018509438 A5 JP2018509438 A5 JP 2018509438A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
replaced
pharmaceutical composition
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017549483A
Other languages
English (en)
Japanese (ja)
Other versions
JP6827948B2 (ja
JP2018509438A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2016/050209 external-priority patent/WO2016149756A1/en
Publication of JP2018509438A publication Critical patent/JP2018509438A/ja
Publication of JP2018509438A5 publication Critical patent/JP2018509438A5/ja
Application granted granted Critical
Publication of JP6827948B2 publication Critical patent/JP6827948B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017549483A 2015-03-23 2016-03-23 呼吸器疾患の治療 Active JP6827948B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901032 2015-03-23
AU2015901032A AU2015901032A0 (en) 2015-03-23 Treatment of respiratory diseases
PCT/AU2016/050209 WO2016149756A1 (en) 2015-03-23 2016-03-23 Treatment of respiratory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021007384A Division JP7169693B2 (ja) 2015-03-23 2021-01-20 呼吸器疾患の治療

Publications (3)

Publication Number Publication Date
JP2018509438A JP2018509438A (ja) 2018-04-05
JP2018509438A5 true JP2018509438A5 (US07846941-20101207-C00217.png) 2019-05-09
JP6827948B2 JP6827948B2 (ja) 2021-02-10

Family

ID=56976881

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017549483A Active JP6827948B2 (ja) 2015-03-23 2016-03-23 呼吸器疾患の治療
JP2021007384A Active JP7169693B2 (ja) 2015-03-23 2021-01-20 呼吸器疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021007384A Active JP7169693B2 (ja) 2015-03-23 2021-01-20 呼吸器疾患の治療

Country Status (5)

Country Link
US (4) US10722513B2 (US07846941-20101207-C00217.png)
EP (1) EP3273955A4 (US07846941-20101207-C00217.png)
JP (2) JP6827948B2 (US07846941-20101207-C00217.png)
CN (3) CN113350353A (US07846941-20101207-C00217.png)
WO (1) WO2016149756A1 (US07846941-20101207-C00217.png)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3273955A4 (en) 2015-03-23 2019-05-01 The University of Melbourne TREATMENT OF RESPIRATORY DISEASES
JP2016193861A (ja) * 2015-03-31 2016-11-17 国立大学法人山梨大学 マスト細胞活性化を抑制するための医薬組成物
TW201837027A (zh) * 2017-02-01 2018-10-16 以色列商以色列耶路撒冷希伯來大學伊索研究發展有限公司 吡唑衍生物及其用途
US20200079757A1 (en) * 2017-05-03 2020-03-12 The University Of Melbourne Compounds for the treatment of respiratory diseases
WO2019090405A1 (pt) * 2017-11-11 2019-05-16 Carvalho Junior Mario Virgilio De Medicamento de ciclesonida para cura e prevenção da gripe causada pelo vírus influenza
JP2022507118A (ja) * 2018-11-07 2022-01-18 ザ ユニヴァーシティー オブ メルボルン 呼吸器疾患の処置のための化合物及び組成物
KR102253324B1 (ko) * 2019-11-27 2021-05-18 단디바이오사이언스 주식회사 호흡기 질환의 예방, 개선 또는 치료용 조성물
WO2021167703A1 (en) 2020-02-19 2021-08-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof
AR122711A1 (es) * 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA
MX2023009682A (es) 2021-02-19 2023-10-30 Sudo Biosciences Ltd Inhibidores de tyk2 y sus usos.
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
EP4333853A1 (en) * 2021-05-03 2024-03-13 Thirona Bio, Inc. Methods for treating a pulmonary disease with an alk-5 (tgf beta r1) inhibitor
CN115792229B (zh) * 2022-01-28 2024-06-18 华中科技大学同济医学院附属同济医院 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用
WO2024091485A1 (en) * 2022-10-25 2024-05-02 The Regents Of The University Of California Compositions and methods for treating or preventing pulmonary fibrosis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
IL110296A (en) 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
KR19980701374A (ko) * 1995-01-12 1998-05-15 스티븐 베네티아너 신규 화합물(Novel Compounds)
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
US6096739A (en) 1996-03-25 2000-08-01 Smithkline Beecham Corporation Treatment for CNS injuries
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
AR017219A1 (es) 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
HUP0301117A3 (en) * 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
WO2004028545A1 (en) 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
CN1968716A (zh) * 2003-01-09 2007-05-23 阿里泽克药品公司 治疗肺疾病的方法
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
PT1713473E (pt) 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd
WO2005103240A1 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with casein kinase 1, delta, isoform 1 (csnk1d iso 1)
CN101031568A (zh) * 2004-06-23 2007-09-05 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
US20090181991A1 (en) * 2005-11-03 2009-07-16 Irm Llc Compounds and compositions as protein kinase inhibitors
US20080051410A1 (en) * 2006-08-02 2008-02-28 Northwestern University Protein Kinase Targeted Therapeutics
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
MY153057A (en) * 2007-02-02 2014-12-31 Pfizer Prod Inc Tryclic compounds,compositions and methods
WO2009039310A2 (en) * 2007-09-18 2009-03-26 La Jolla Institute For Allergy And Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
WO2009047163A1 (en) * 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
WO2009158587A1 (en) * 2008-06-26 2009-12-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
KR20110091505A (ko) 2008-10-14 2011-08-11 악티바에로 게엠베하 Copd 및 기타 폐질환의 치료 방법
FR2943058B1 (fr) 2009-03-11 2011-06-03 Centre Nat Rech Scient Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
WO2011056697A1 (en) * 2009-10-28 2011-05-12 Medimmune, Llc Topical methods of treating rsv infections and related conditions
PT2493876E (pt) 2009-10-28 2014-03-20 Pfizer Derivados de imidazol como inibidores de caseína cinase
CA2795765C (en) * 2010-04-06 2020-07-07 Fred Hutchinson Cancer Research Center Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
EP2589385A1 (en) * 2011-11-03 2013-05-08 Fundación Centro Nacional de Investigaciones Oncológicas Triple combination for the treatment of cancer
WO2014018691A1 (en) 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Generation of airway and lung progenitors and epithelial cells and three-dimensional anterior foregut spheres
CZ2012538A3 (cs) 2012-08-08 2014-02-19 Masarykova Univerzita Inhibitory pro léčbu B-buněčné chronické lymfocytární leukémie
JP5990862B2 (ja) 2012-10-01 2016-09-14 国立研究開発法人科学技術振興機構 承認予測装置、承認予測方法、および、プログラム
CN103784451A (zh) * 2012-10-31 2014-05-14 无锡蕾明视康科技有限公司 一种治疗抑郁症的药物
JP6267231B2 (ja) 2012-12-21 2018-01-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カゼインキナーゼ1δ/ε阻害剤としての新規な置換イミダゾール
US9475817B2 (en) * 2012-12-21 2016-10-25 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
CN111068053A (zh) 2014-02-03 2020-04-28 耶路撒冷希伯来大学的益生研究开发有限公司 使用酪蛋白激酶i抑制剂以消耗干细胞的用途
EP3273955A4 (en) 2015-03-23 2019-05-01 The University of Melbourne TREATMENT OF RESPIRATORY DISEASES
JP2016193861A (ja) 2015-03-31 2016-11-17 国立大学法人山梨大学 マスト細胞活性化を抑制するための医薬組成物
WO2017083971A1 (en) 2015-11-16 2017-05-26 University Of Manitoba Compositions and methods for treatment of influenza
US11124841B2 (en) 2016-10-28 2021-09-21 University Of Utah Research Foundation Methods and compositions for identifying and treating patients with small cell lung cancer
US20200079757A1 (en) 2017-05-03 2020-03-12 The University Of Melbourne Compounds for the treatment of respiratory diseases
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
EP3846818A1 (en) 2018-09-09 2021-07-14 Qanatpharma AG Use of casein kinase 1 inhibitors for treating vascular diseases

Similar Documents

Publication Publication Date Title
JP2018509438A5 (US07846941-20101207-C00217.png)
JP2019034943A5 (US07846941-20101207-C00217.png)
JP2019094345A5 (US07846941-20101207-C00217.png)
JP2020537657A5 (US07846941-20101207-C00217.png)
JP2017533968A5 (US07846941-20101207-C00217.png)
JP2020183410A5 (US07846941-20101207-C00217.png)
JP2020509022A5 (US07846941-20101207-C00217.png)
JP2013542267A5 (US07846941-20101207-C00217.png)
JP2013056930A5 (US07846941-20101207-C00217.png)
JP2016512531A5 (US07846941-20101207-C00217.png)
JP2019520396A5 (US07846941-20101207-C00217.png)
JP2010539110A5 (US07846941-20101207-C00217.png)
JP2018515495A5 (US07846941-20101207-C00217.png)
JP2019504890A5 (US07846941-20101207-C00217.png)
JP2018536648A5 (US07846941-20101207-C00217.png)
JP2010540593A5 (US07846941-20101207-C00217.png)
JP2017502006A5 (US07846941-20101207-C00217.png)
JP2018524304A5 (US07846941-20101207-C00217.png)
JP2012255002A5 (US07846941-20101207-C00217.png)
JP2019524883A5 (US07846941-20101207-C00217.png)
JP2010540602A5 (US07846941-20101207-C00217.png)
JP2019519616A5 (US07846941-20101207-C00217.png)
JP2018515563A5 (US07846941-20101207-C00217.png)
JP2015520738A5 (US07846941-20101207-C00217.png)
JP2014524476A5 (US07846941-20101207-C00217.png)